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disorder.	Although	IBS	 is	a	benign	condition,	 it	 reduces	the	quality	of	 life	consider-
ably.	While	there	is	currently	no	effective	treatment	for	this	disorder,	fecal	microbiota	
transplantation	(FMT)	seems	to	be	promising.









while the other three did not find any effect.
Conclusions and Inferences: The	 efficacy	 of	 FMT	 for	 IBS	 appears	 to	 be	 donor-	
dependent.	The	effective	 (super)	 donor	would	need	 to	have	a	 favorable	microbiota	
signature,	and	11	clinical	criteria	that	are	known	to	be	associated	with	a	favorable	mi-
crobiota	have	been	suggested	for	selecting	FMT	donors	for	IBS.	Comparing	the	micro-
biota of the effective donors with those of healthy subjects would reveal the favorable 
microbiota	signature	required	for	a	super-	donor.	However,	the	studies	reviewed	were	
not designed to compare efficacy of different donor types. The dose of the fecal trans-
plant	is	also	an	important	factor	influencing	the	outcome	of	FMT	for	IBS.	However,	fur-
ther studies designed to test the effect of fecal transplant dose are needed to answer 
this	question.	Administering	the	fecal	transplant	to	either	the	small	or	large	intestine	
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1  |  INTRODUC TION
Irritable	bowel	syndrome	(IBS)	is	a	chronic	disorder	affecting	11.2%	
of	 the	 world's	 population,	 with	 the	 highest	 prevalence	 in	 South	
America	and	the	lowest	prevalence	in	South	Asia.1,2 IBS is a benign 
disorder	that	is	not	associated	with	increased	mortality,	and	it	does	
not develop into a serious disease.3	However,	IBS	reduces	the	qual-
ity of life of the affected patients considerably.1 There is no effective 
treatment	 for	 IBS,	with	 the	available	 treatments	being	directed	at	
symptom relief.4
The	 etiology	 of	 IBS	 is	 unknown,	 but	 the	 intestinal	 microbiota	
seems to play a pivotal role in its pathophysiology.1 The intestinal 
bacterial profile in IBS patients differs from that in healthy sub-
jects.5-	12 IBS patients have also a lower diversity of gut bacteria 
(dysbiosis)	 than	healthy	 subjects.5-	10 Fecal microbiota transplanta-
tion	 (FMT)	 has	 been	 applied	 to	 IBS	 patients	 in	 seven	 randomized	
controlled	trials	(RCTs),13-	19 four of which showed a positive effect 
13,15,18,19 while the other three showed no effect.14,16,17	At	first	sight,	
it appears to be challenging to compare these RCTs due to variations 
in	the	criteria	used	to	select	the	donors	and	patients,	in	the	dose	of	
the	 fecal	 transplant	used,	and	 in	 the	FMT	protocols.	Furthermore,	





ite responder endpoint.20,21	While	 reduction	 in	 IBS-	SSS	score	was	
used	5	RCTs	to	measure	the	efficacy	of	FMT,13,14,16-	18 relief of gen-
eral IBS symptoms and abdominal bloating was used in one RCT.19 
Recommendations	 for	 consideration	 in	 future	 FMT	 studies	 in	 IBS	
concerning several topics of investigation have been suggested for 
improving	the	outcome	of	FMT	in	IBS.22,23
Benech	 and	 Sokol	 considered	 that	 the	 application	 of	 FMT	 in	







2  |  DONOR SELEC TION
The	response	to	FMT	in	inflammatory	bowel	disease	(IBD)	appears	
to	be	donor-	dependent,	with	variations	 in	the	study	outcomes	ex-
plainable by differences between the donors.5,25 This situation has 
led	to	the	term	super-	donor	being	coined	to	describe	a	donor	that	
induces desirable effects in recipients.5 Since there are no clear 
criteria	 for	 the	 super-	donor,	 predicting	 the	 clinical	 efficacy	 of	 the	
donor	before	FMT	is	impossible.	Attempts	to	overcome	this	obstacle	
have led to suggestions that donors’ feces should be pooled in order 
to	 increase	 the	 likelihood	 of	 patients	 receiving	 effective	 feces.26 
However,	applying	this	approach	did	not	increase	the	response	rate	
to	 FMT,	 which	 is	 probably	 because	 the	 feces	 of	 the	 super-	donor	
would	be	diluted	and	consequently	the	recipients	would	not	receive	
a	sufficient	dose	from	the	super-	donor.27
The donors in all of the RCTs done on IBS patients were healthy 
and	had	a	normal	body	mass	index	(BMI).13-	19	The	super-	donor	for	the	
IBS patients was selected based either on clinical efficacy in a pilot 
trial or on clinical criteria and the fecal microbiota profile.15,17,19,28 
The	RCT	of	Holvoet	and	colleagues	used	two	donors	who	were	ef-
fective in a pilot trial.19,28	Another	RCT	 selected	 two	donors	who	
had	the	highest	fecal	abundance	of	the	butyryl-	CoA	CoA	transferase	
gene.17	El-	Salhy	et	al	used	both	clinical	criteria	and	the	fecal	bacterial	
profile when choosing a single donor.15 The basis for choosing the 











diet are associated with a favorable gut microbiota.38-	40	Furthermore,	
since	the	intestinal	microbiota	is	affected	by	the	genetic	composition,	
the	super-	donor	should	not	be	a	first-	degree	relative	of	any	recipient,	






did not show any effect seems to be effective.
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being	healthy	with	a	normal	BMI,	a	young	male	(37	years	old),	born	via	
a	vaginal	delivery,	breastfed,	and	a	non-	smoker,	not	taking	any	med-
ication,	 having	been	 treated	only	 a	 few	 times	with	 antibiotics,	 and	
regularly performing physical exercise. The donor's diet was within 
the	normal	range	of	those	consumed	by	35	healthy	subjects	as	mea-
sured	by	the	MoBa	Food	Frequency	Questionnaire,	but	he	consumed	
also	a	 sport-	specific	diet	 that	was	 richer	 in	protein,	 fiber,	minerals,	







included an abundance of Streptococcus,	 Dorea,	 Lactobacillus,	 and	
Ruminococcaceae spp. These four genera of bacteria have been re-
ported to constitute favorable bacteria for a donor.5,28,44,45
Holvoet	 et	 al	 observed	 that	 the	 fecal	 bacterial	 composition	of	
one	 of	 the	 two	 donors	 they	 used	was	 stable	 over	 time,	 and	 that	
donor was more effective than the second donor whose fecal bac-
terial composition varied over time.19	Based	on	these	observations,	
those	authors	concluded	that	next	to	a	high	bacterial	diversity,	sta-
bility of the bacterial composition over time is also an important fac-
tor when selecting an effective donor.19 It is noteworthy that the 




or only a transient improvement.13,14	Thus,	pooling	donor	 feces	 in	
IBS	(like	in	IBD)	is	not	recommended.
F I G U R E  1 The	super-	donor	bacterial	profile	deviated	from	the	expected	normal	abundance	in	14	of	the	39	bacteria	markers.	The	
deviating bacteria belong to the typical commensal bacteria species that do not contribute to dysbiosis. Twelve of these bacteria belong 
to	the	phylum	Firmicutes	(gray),	one	to	the	phylum	Proteobacteria	(light	green),	and	one	to	the	phylum	Verrucomicrobia	(light	blue).	
Reproduced	from	El-	Salhy	et	al15 with permission from the authors and publisher.
F I G U R E  2 Scaled	PCA	plot	of	fecal	samples	from	the	super-	
donor and patients before transplantation. The patient samples 
are	indicated	by	small	gray	circles.	The	super-	donor	samples	are	





et al.15 with permission from the authors and publisher.
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The	donor	in	the	RCT	of	Lahtinen	et	al	was	a	healthy	young	adult	
male	with	a	normal	BMI	who	was	born	via	 a	vaginal	delivery,	had	
not	 taken	 antibiotics	 during	 the	 previous	 year,	 and	was	 not	 using	
any permanent medications.18	Thus,	6	of	the	11	clinical	criteria	for	
an	effective	donor	described	by	El-	Salhy	et	al	were	 fulfilled15; the 
remaining	 criteria	 are	 breastfeeding,	 not	 smoking,	 regularly	 per-





lasting	effect	in	most	patients	at	1	year	after	FMT.15,18,46 It is difficult 
to speculate as to which of the five factors was responsible for the 
difference	in	the	outcomes	between	these	two	RCTs.	However,	the	
donor's	diet	 in	 the	RCT	of	El-	Salhy	et	 al	might	have	been	a	major	
factor,	 since	dietary	modifications	and	nutritional	 supplements	 in-
fluence the intestinal microbiota.47
The selection of donors in the two RCTs that produced the most 
positive	 effects	 of	 FMT	 in	 IBS	patients	was	 based	 either	 on	 clini-
cal efficacy in a pilot trial or on the donor's specific characteristics 




lored microbial consortia.48 This would also allow the identification 
of the beneficial microbiota of the donors and their probable recon-
stitution in the laboratory.48 To identify the presence of a favorable 
signature	in	a	donor,	their	bacterial	profile	should	be	compared	with	




clinical outcome.24 It is worthy of note that in the successful RCTs of 
FMT	for	IBS	male	donors	were	used,15,18,19 whether the sex of the 
donor	plays	a	role	in	the	outcome	of	FMT	for	IBS	patients	remains	
to be determined.




IBS-	D	 and	 IBS-	M	 were	 investigated	 in	 four	 of	 the	 RCTs,13,16,18,19 
and	those	with	IBS-	D,	IBS-	C,	and	IBS-	M	were	included	in	the	other	
three.14,15,17	Furthermore,	different	subsets	of	IBS	patients	were	in-





Care	Excellence)-	modified	diet	for	at	least	3	months.15 Only IBS pa-
tients	with	low	amounts	of	fecal	butyrate-	producing	bacteria	were	
included	in	the	RCT	of	Holster	et	al.17 Refractory IBS patients with 
severe bloating who had failed to respond to at least three conven-
tional	therapies	for	IBS	were	included	in	the	study	of	Holvoet	et	al.19 
Such restriction to subsets of IBS patients indicates the need for 
caution when attempting to draw general conclusions from these 
RCTs that apply to the entire IBS population.
4  |  DOSAGE, ROUTE OF ADMINISTR ATION, 
AND FORM OF THE FECAL TR ANSPLANT
Increasing	 the	 dose	 of	 the	 fecal	 transplant	 from	 30	 g	 to	 60	 g	 in-
creased	the	response	to	FMT	in	IBS	patients,	suggesting	the	pres-
ence	 of	 a	 dose-	dependent	 response	 similar	 to	 that	 described	






fied.16,19 The efficacy of single versus repeated transplantation re-
quires	further	investigation.
Administering	 the	 fecal	 transplant	 to	 either	 the	 small	 or	 large	
intestine seems to be effective.13,15,17-	19	However,	 the	placebo	ef-




(23.6%–	26%).13,15,17-	19 The higher placebo response in those studies 
that used colonoscopy to administer the fecal transplant could be 
explained	by	the	procedure	itself,	since	colonoscopy	requires	bowel	




to the small or large intestine remains to be determined in future 
studies.
Administering	a	fecal	transplant	via	capsules	was	not	effective	
in IBS.14,16 This is unfortunate given the ease of administration 
using this method and it being more acceptable to the patients. The 
lack	of	response	in	the	RCTs	that	used	capsules	to	administer	donor	
fecal	transplants	could	be	due	to	other	factors,	such	as	the	selected	
donors,	 a	 low	 transplant	 dose,	 and/or	 pooling	 of	 the	 donors.14,16 
The capsule administration route for fecal transplants has been 
successful in CDI. 46 Further studies exploring the effectiveness of 




cacious.13,15,18,52-	54 This observation avoids the logistical problems 
associated with using fresh donor’ feces and facilitates the use of 
FMT	in	the	clinic.	Moreover,	 it	makes	it	possible	to	establish	feces	
banks	for	the	routine	clinical	use	of	FMT.
    |  5 of 8EL- SALHY Et AL.
5  |  SAFET Y ISSUES OF FMT FOR IBS
The	adverse	events	reported	in	FMT	for	IBS	patients	after	a	1-	year	
observation time are summarized in Table 1. These adverse events 
were	mild,	self-	limiting,	and	only	occurred	during	the	first	few	days	
after	 FMT.	 Patients	 treated	 with	 FMT	 experienced	more	 adverse	




these	 two	 patients	 had	 known	 diverticulosis	 and	 experienced	
several	diverticulitis	attacks	before	FMT,	and	so	it	is	difficult	to	es-
tablish	whether	these	new	attacks	were	causally	connected	to	FMT.
Two patients were recently reported to have developed serious 
adverse	events	after	FMT	for	other	indications	than	IBS,	which	re-
sulted in one fatality.55,56 These events have started a discussion 
about	safety	issues	around	FMT	for	IBS,	especially	considering	that	
IBS is a benign gastrointestinal condition.48,57,58 The two patients 
involved	in	these	events	were	immunosuppressed	69	and	73	years	
old with advanced liver cirrhosis and myelodysplastic syndrome. 
They received fecal capsules derived from a donor who had an 
antibiotic-	resistant	Escherichia coli strain.55,56 It has been suggested 
that	screening	of	FMT	donors	should	include	testing	the	donor	feces	






6  |  POSSIBLE MECHANISMS UNDERLYING 
THE EFFEC TS OF FMT
While it is too early to definitively identify the mechanisms under-
lying	the	positive	effects	of	FMT,	several	observations	have	been	
made that may shed light on such mechanisms. The fecal levels 
of	 total	 short-	chain	 fatty	acids	 (SCFAs)	 increased	 in	 IBS	patients	
after	1	month	and	remained	elevated	at	1	year	following	FMT.46,59 
SCFAs	 regulate	 intestinal	motility	and	 the	secretion	and	absorp-
tion of water and electrolytes.60,61	These	effects	of	SCFAs	seem	
to	 be	 caused	 by	 increasing	 the	 secretion	 and	 up-	regulating	 the	





F I G U R E  3 Responses	of	IBS	patients	
to	placebo,	30-	g	FMT	and	60-	g	FMT	at	
different intervals after transplantation. 
**,	p<0.001; ****,	p<0.0001 compared 
with placebo. *p < 0.001; ***p < 0.0001 
for	30-	g	FMT	compared	with	60-	g	
FMT.	Reproduced	from	El-	Salhy	et	al15 
with permission from the authors and 
publisher.
F I G U R E  4 The	IBS-	SSS	total	score	of	patients	who	did	not	
respond	to	a	30-	g	transplant	and	received	a	60-	g	transplant	at	
3–	4	months	after	the	first	transplant.	*p < 0.05 compared to 
baseline.	Reproduced	from	El-	Salhy	et	al48 with permission from 
the authors and publisher.
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This	increase	could	be	explained	by	the	increased	levels	of	butyrate-	
producing Eubacterium and Lactobacillus spp.15,65-	67 Butyrate is an 
important	source	of	energy	for	colonic	epithelial	cells,	and	it	affects	
the	 immune	 response,	modulates	 the	oxidative	 stress	of	 the	host,	
and	decreases	intestinal-	cell	permeability	and	intestinal	motility.61,64 
Moreover,	 butyrate	modulates	 colonic	 hypersensitivity,	 and	 treat-
ment with butyrate reduces abdominal pain in patients with IBS.68-	70 
Interestingly,	following	FMT	in	IBS	patients,	the	levels	of	butyric	acid	




acids	were	observed	 in	 IBS	patients	 at	 1	 year	 of	 FMT,	 suggesting	
a shift in microbial fermentation from a saccharolytic to a proteo-
lytic	 pattern,	which	might	 be	 of	 pathophysiological	 relevance.46,71 
Moreover,	the	level	of	the	straight	SCFA	acetic	acid	decreased	sig-
nificantly	at	1	year	after	FMT,46 which could be important given that 
acetic acid induces visceral hypersensitivity in rodents.72
7  |  CONCLUSION AND PERSPEC TIVE
FMT	appears	to	be	a	promising	treatment	for	IBS.	The	outcome	of	
FMT	is	donor-	dependent,	indicating	the	need	for	care	when	select-
ing donors. Clinical criteria that are associated with a favorable mi-
crobiota	signature	have	been	proposed.	However,	it	is	not	yet	clear	
whether some of these criteria are more important than others or 
whether	all	of	the	criteria	should	be	satisfied	in	an	effective	(super)	
donor. Future studies should test the reliability of these criteria 
and also compare the microbial signatures between the donor and 
healthy subjects.
The dose of the fecal transplant is important to the effi-
cacy	of	FMT,	with	doses	 lower	 than	30	g	not	 showing	any	effect.	
Administering	the	fecal	transplant	to	either	the	small	or	large	intes-
tine	is	effective,	but	further	studies	are	needed	to	establish	which	
route is optimal. Whether the effectiveness differs between single 
and	repeated	FMT	also	remains	to	be	determined.
CONFLIC T OF INTERE S T
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TA B L E  1 Adverse	events	reported	following	fecal	microbiota	transplantation	(FMT)	in	patients	with	irritable	bowel	syndrome
Study
Nausea Abdominal pain Diarrhea Constipation
Bloating/
flatulence Diverticulitis
Placebo FMT Placebo FMT Placebo FMT Placebo FMT Placebo FMT Placebo FMT
Johnsen	et	al	(2018)13 0 0 7 2 0 0 0 0 0 0 0 0
Halkjær	et	al	(2018)14 27 35 19 27 0 23* 0 12 4 19 0 0
Holster	et	al	(2019)17 25 0 38 38 25 25 0 13 38 38 0 0
Aroniadis	et	al	(2019)16 8 4 10 8 6 17 0 0 0 0 0 0
El-	Salhy	et	al	(2020)15 16 16 0 21*** 4 24*** 2 22*** 0 0 0 2
Lahtinen	
et	al	(2020)18,54
0 0 0 0 4 17 0 0 8 13 0 0
Note: Values are percentages.
*p <	0.05,;	***p < 0.001 compared to placebo.
F I G U R E  5 Correlation	between	butyric	acid	levels	and	IBs-	SSS	
total	scores	(A)	and	FAS	total	score	(B).	Reproduced	from	El-	Salhy	
et al62 with permission from the authors and publisher.
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